BLA 206538 · Sanofi US Services
Toujeo Solostar
Insulin Glargine Recombinant · Subcutaneous · Insulin Analog
Last checked: Nov 20, 2026Latest source record: Aug 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Feb 25, 2015
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
9
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Glargine Recombinant" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) PatientsPivotal-lookingCompleted
Emory UniversityAcademic, hospital or other
NCT01792830 · 175 participants · Start Oct 2012 · Primary completion Feb 2014
Drug: Metformin; Glargine insulin and 1 more · For: Poor Glycemic Control
Sites: Atlanta, Georgia · 3 sites in all
- Insulin in Total Parenteral NutritionPivotal-lookingCompleted
Fundación Pública Andaluza Progreso y SaludAcademic, hospital or other
NCT02706119 · 163 participants · Start Jul 1, 2016 · Primary completion Mar 31, 2018
Drug: Subcutaneous glargine insulin; Regular insulin added to TPN bag · For: Diabetes Mellitus
Sites: Ferrol, Spain; Mérida, Spain; Palma de Mallorca, Spain · 32 sites in all
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes MellitusPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01194245 · 135 participants · Start Aug 2010 · Primary completion Aug 2011
Drug: Insulin lispro; recombinant human hyaluronidase PH20 and 3 more · For: Diabetes Mellitus, Type 1
Sites: Escondido, California; La Jolla, California; San Mateo, California · 19 sites in all
- Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01194258 · 132 participants · Start Aug 2010 · Primary completion Aug 2011
Drug: Insulin lispro; Insulin aspart and 3 more · For: Diabetes Mellitus, Type II
Sites: Concord, California; Encino, California; Escondido, California · 22 sites in all
- Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DMPivotal-lookingCompleted
WockhardtIndustry
NCT01357603 · 111 participants · Start Jun 2011 · Primary completion May 2012
Drug: Glargine · For: Type1 Diabetes
Sites: Chula Vista, California
Cook County HealthGovernment (non-federal)
NCT00732524 · 80 participants · Start Sep 2004 · Primary completion Apr 2006
Drug: Glipizide; Glipizide and Glargine · For: Type 2 Diabetes
Sites: Chicago, Illinois
Halozyme TherapeuticsIndustry
NCT00883558 · 48 participants · Start May 2009 · Primary completion Feb 2010
Drug: Insulin Lispro; regular human insulin and 2 more · For: Diabetes Mellitus, Type 1
Sites: Aurora, Colorado; Miami, Florida; Detroit, Michigan · 8 sites in all
- Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic PatientsPivotal-lookingWithdrawn
WockhardtIndustry
NCT01352663 · 0 participants
Drug: Wockhardt's Insulin Analogue (Recomb); Lantus® · For: Type I Diabetes
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Toujeo Max Solostar (Insulin Glargine,Hum.Rec.Anlog)
2024 spending
$561M
Beneficiaries
134,394
514,108 claims
Per beneficiary
$4,176
$88.80 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $205,860,575 |
| 2021 | $285,075,587 |
| 2022 | $356,666,504 |
| 2023 | $488,777,502 |
| 2024 | $561,185,695 |
Part D: Toujeo Solostar (Insulin Glargine,Hum.Rec.Anlog)
2024 spending
$550M
Beneficiaries
189,494
762,959 claims
Per beneficiary
$2,902
$88.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $569,974,166 |
| 2021 | $540,910,610 |
| 2022 | $505,159,441 |
| 2023 | $541,871,908 |
| 2024 | $549,974,619 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Sanofi · Also marketed as Toujeo Max Solostar
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.